Cargando…

Evaluation of efalizumab using safe psoriasis control

BACKGROUND: Safe Psoriasis Control (SPC) is an important comprehensive measure that is validated for the assessment of benefit:risk of psoriasis treatments, combining efficacy, quality of life, and safety measures. The objective of this analysis was to assess the benefit:risk of efalizumab, a novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papp, Kim A, Henninger, Eric
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592297/ https://www.ncbi.nlm.nih.gov/pubmed/16984639 http://dx.doi.org/10.1186/1471-5945-6-8

Ejemplares similares

Efalizumab in the treatment of psoriasis
por: Boehncke, Wolf-Henning
Publicado: (2007)

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
por: Pincelli, Carlo, et al.
Publicado: (2006)

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]
por: Ortonne, Jean-Paul, et al.
Publicado: (2005)

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
por: Lowes, Michelle A, et al.
Publicado: (2007)

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence
por: Papp, Kim A, et al.
Publicado: (2006)

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis
por: Leonardi, C, et al.
Publicado: (2008)

Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series
por: Lowes, Michelle A, et al.
Publicado: (2005)

Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study
por: Takahashi, María Denise, et al.
Publicado: (2010)

Efalizumab-induced severe thrombocytopenia can be resolved
por: Prignano, Francesca, et al.
Publicado: (2008)

Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results
por: Stengel, Fernando M, et al.
Publicado: (2009)

Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial
por: Katsambas, Andreas, et al.
Publicado: (2009)

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
por: Lotti, Torello, et al.
Publicado: (2010)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

The long-term efficacy and safety of new biological therapies for psoriasis
por: Papp, Kim A.
Publicado: (2006)

Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic
por: De, Abhishek, et al.
Publicado: (2019)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients
por: Burlando, Martina, et al.
Publicado: (2022)

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis
por: Anil Kumar, Mysore S., et al.
Publicado: (2018)

Evaluation of Corneal Biomechanical Parameters in Psoriasis Patients: A Controlled Study
por: Edris, Noha A, et al.
Publicado: (2020)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study
por: Strand, Vibeke, et al.
Publicado: (2013)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials
por: Papp, Kim A., et al.
Publicado: (2015)

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
por: Armstrong, April W., et al.
Publicado: (2018)

Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review
por: Papp, Kim A., et al.
Publicado: (2021)

Evaluation of ocular psoriasis with meibography()
por: Kemeriz, Funda, et al.
Publicado: (2022)

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis
por: Valenzuela, Fernando, et al.
Publicado: (2015)

Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study
por: Weisel, Kathleen, et al.
Publicado: (2020)

Evaluation of renal function in patients with psoriasis using immunobiologicals
por: Melgaço, Sarah Suyanne Carvalho, et al.
Publicado: (2013)

Evaluation of the relationship between migraine and psoriasis: a case-control study()
por: Sarkhani, Mohamad, et al.
Publicado: (2023)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Is "safe effective glucose control" effective and safe?
por: Schultz, Marcus J, et al.
Publicado: (2008)

Ultrasound Evaluation of the Effectiveness of the Use of Acitretin in the Treatment of Nail Psoriasis
por: Krajewska-Włodarczyk, Magdalena, et al.
Publicado: (2021)

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
por: Adsit, Sandra, et al.
Publicado: (2017)

Diffusion weighted imaging for the detection and evaluation of cholesteatoma
por: Henninger, Benjamin, et al.
Publicado: (2017)

On the Use of Arsenic in Psoriasis
Publicado: (1807)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tjnaimcfljuqme3baruftq4li4